2-benzyloxycarbamoyl-4-methyl-pentanoic acid | 87438-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyloxycarbamoyl-4-methyl-pentanoic acid
• 英文别名: 4-methyl-2-(phenylmethoxycarbamoyl)pentanoic acid
• CAS: 87438-95-7
• 化学式: C₁₄H₁₉NO₄
• 分子量: 265.309
• InChiKey: DIKULMIBGQPSJS-UHFFFAOYSA-N

物化性质

• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyloxycarbamoyl-4-methyl-pentanoic acid 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 13.0h， 生成 N-(2-Benzylcarbamoyl-phenyl)-N'-hydroxy-2-isobutyl-malonamide
  参考文献：
  名称：

  Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8)

  摘要：

  For most of the known synthetic inhibitors of matrix metalloproteinases (MMPs), a substrate-like binding mode was postulated on the basis of X-ray crystallographic structures of MMP/inhibitor complexes. Conversely, the malonic acid-based inhibitor (2R,S)-HONH-CO-CH(i-Bu)-CO-Ala-Gly-NH2 was found to bind in a surprisingly different manner. Using this compound as a new lead structure, the interaction sites with human neutrophil collagenase (MMP8) were optimized with a series of iteratively designed analogues and with the help of X-ray structural analysis of selected inhibitors to finally produce low molecular weight nonpeptidic compounds of 500-1000-fold improved inhibitory potency.

  DOI：

  10.1021/jm9706426
• 作为产物：
  描述：

  异丁基丙二酸二乙酯 在 氢氧化钾 、 水 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 157.0h， 生成 2-benzyloxycarbamoyl-4-methyl-pentanoic acid
  参考文献：
  名称：

  Hydroxamic Acids as Potent Inhibitors of Endothelin-Converting Enzyme from Human Bronchiolar Smooth Muscle

  摘要：

  Hydroxamic acids 6a-h, derived from malonyl amino acids, and 25a-d, derived from succinyl amino acids, were synthesized as inhibitors of human bronchiolar smooth muscle endothelin-converting enzyme (HBSM ECE). Several unexpected side reactions were discovered, particularly in the synthesis of hydroxamates derived from succinates. In vitro evaluation against human bronchiolar ECE revealed that in all cases hydroxamates derived from malonate were more potent than hydroxamates derived from succinate. Isopropyl and isobutyl P-1' side chains were suitable; omission of the P-1' Side chain seriously diminished potency. In the P-2' position, several amino acids gave potent malonate-derived hydroxamate inhibitors (6b,d-h, IC50 = 0.2-6.8 nM), and beta-Ala provided an extremely potent inhibitor (6c, IC50 = 0.01 nM). C-terminus carboxylates are much more potent ECE inhibitors than the corresponding amides. Most of the hydroxamates were also potent inhibitors of thermolysin and neutral endopeptidase (NEP); however, the P-2' beta-Ala derivative 6c uniquely inhibited HBSM ECE much more potently than NEP.

  DOI：

  10.1021/jm00012a011

文献信息

• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：Allegretti Paul

  公开号：US20090270473A1

  公开（公告）日：2009-10-29

  The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及具有以下式的化合物：其中：Q、W、Y、Z、r 和 Ar 如规范中所定义，并其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting antihypertensive agents
  申请人：Theravance, Inc.

  公开号：US07989484B2

  公开（公告）日：2011-08-02

  The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下式子的化合物：其中：Q，W，Y，Z，r和Ar如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。本发明还涉及包含这些化合物的制药组合物，使用这些化合物的方法以及制备这些化合物的过程和中间体。
• US4618708A
  申请人：——

  公开号：US4618708A

  公开（公告）日：1986-10-21
• US4738803A
  申请人：——

  公开号：US4738803A

  公开（公告）日：1988-04-19
• US7989484B2
  申请人：——

  公开号：US7989484B2

  公开（公告）日：2011-08-02